Concerns are mounting over a recent decision by NHS England that grants Palantir Technologies unrestricted access to identifiable patient data, a move critics label “dangerous.” This controversial development comes as the US tech firm is set to employ artificial intelligence to create an integrated health data platform, raising significant questions about data privacy and public trust.
Unchecked Access to Sensitive Data
Reports indicate that NHS England has permitted staff from Palantir and other contractors to access patient information before it has been pseudonymised. This decision has sparked outrage among Members of Parliament (MPs) and campaigners, who fear it could lead to a breach of patient confidentiality and erode public confidence in the health service.
An internal briefing, leaked to the Financial Times, revealed that the NHS would provide “unlimited access to non-NHSE staff” to portions of its federated data platform (FDP), which houses sensitive patient information. Critics argue that such access contradicts prior assurances from NHS England that personal data would be safeguarded and remain within the NHS.
Calls for Transparency and Accountability
The Patients Association has voiced its concerns, emphasising that patients were not consulted about this significant shift in data access protocols. Chief Executive Rachel Power stated, “Patients want transparency, clear boundaries around access to their data, and to be consulted when changes to those agreements are proposed.” This sentiment echoes broader public unease about the implications of involving a private company like Palantir in the management of NHS data.
Palantir, which has previously been associated with controversial projects, including immigration enforcement and military operations, was awarded a £330 million contract to assist in developing the FDP. The company asserts that it functions solely as a “data processor,” with strict controls in place to ensure compliance with NHS guidelines. However, this reassurance has not quelled concerns over potential misuse of data.
Political Pressure and Public Distrust
Rachael Maskell, the Labour MP for York Central and a former NHS worker, has been vocal in her opposition to the Palantir initiative. She warned that as the company deepens its involvement with NHS data, it potentially opens the door to greater private sector influence within public healthcare. “This is a dangerous development,” she stated, urging the government to take decisive action before it is too late.
A Liberal Democrat member of the Commons technology select committee, Martin Wrigley, highlighted the need for robust data security measures, stating, “This somewhat cavalier attitude to data security demonstrates how this whole project does not have security by design at its heart.” Public opinion appears to back these concerns, with recent polling indicating that over two-thirds of UK citizens express unease about Palantir’s expanding role in public contracts.
A Growing Backlash Against Palantir
Palantir’s involvement in the UK public sector is increasingly contentious. Recent reports also suggested that the company is nearing a deal with the Metropolitan Police to utilise AI for intelligence analysis in criminal investigations. This escalating presence has prompted widespread discontent, with many citizens and MPs demanding an end to its association with public services.
Tom Hegarty, head of communications at the tech equity group Foxglove, remarked, “NHS patients never consented to have their data accessed by a company like Palantir whose record is in targeting people, not caring for them. Once again: Palantir fails the trust test.” The sentiment reflects a growing distrust in the government’s ability to protect sensitive patient information.
Why it Matters
The decision to grant Palantir extensive access to NHS patient data raises fundamental questions about privacy, consent, and the role of private companies in public healthcare. As public awareness and concern over data security grow, it is vital for the government to address these issues transparently and decisively. The outcome of this situation could have far-reaching implications for patient trust and the integrity of the NHS, which relies on the public’s confidence in its ability to safeguard personal health information.
